Indefinite Delivery Contract 75D30118D01508
Award Date
7/1/18
Last Date to Order
6/30/19
Federal Agency
CDC Pittsburgh
Awardee
Glaxosmithkline, LLC
Ultimate Awardee
Not listed
PSC Category
6505 - Drugs And Biologicals
Federal Contract Vehicle
Pricing Type
Firm Fixed Price
Legislative Mandate
Not listed
National Interest Action
None
Award Type
Single
Primary Consortia Member
Not listed
Similar IDVs
The indefinite delivery contract (IDV) with ID 75D30119D05108 was awarded to Glaxosmithkline, LLC by the Centers for Disease Control and Prevention (CDC) for the delivery of adult vaccines. The $112,644,450 multiple award contract, which does not have any set-aside designations, has a period of performance from July 1, 2019 to June 30, 2024. Under this IDV, Glaxosmithkline provides a range of pharmaceutical goods and services as the prime contractor, including influenza virus and hepatitis...
This indefinite-delivery, indefinite-quantity (IDIQ) contract was awarded by the Centers for Disease Control and Prevention (CDC), National Center for Immunization and Respiratory Diseases, to Glaxosmithkline, LLC, a pharmaceutical company, for the purchase of 12 standard adult vaccines. The $172.4 million contract has a one-year period of performance from July 1, 2022 to June 30, 2023 and does not utilize any set-asides. The vaccines, which include influenza, hepatitis, pneumococcal, and...
The federal contract IDV award is a $13,916,000 Indefinite Delivery Contract issued by the Centers for Disease Control and Prevention (CDC) to GlaxoSmithKline, LLC to provide adult influenza vaccines for the 2025-2026 season. The contract has a period of performance through February 28, 2026. GlaxoSmithKline, a pharmaceutical company that supplies vaccines and other products to federal agencies, will deliver the seasonal flu vaccines under this multiple award IDV contract. The contract vehicle...
This indefinite delivery contract (IDC) was awarded by the Centers for Disease Control and Prevention (CDC) to Glaxosmithkline, LLC to procure a variety of adult vaccines over a 1-year period from July 1, 2021 to June 30, 2022. The $156,027,900 multiple award IDC contains no set-aside designation and requires delivery within 15 business days of order placement to destinations across the United States to support state health departments and immunization programs. The original solicitation...
The indefinite delivery contract (IDC) 75D30120D08572 was awarded by the Centers for Disease Control and Prevention (CDC) to Glaxosmithkline, LLC for the provision of vaccines for adults. The $131,225,875 multiple award contract has a period of performance through June 30, 2021. Glaxosmithkline, a pharmaceutical company, will supply a range of vaccines and antiviral medications to support disease prevention efforts, immunization programs, and healthcare services for various U.S. government...
This indefinite delivery contract was awarded by the Centers for Disease Control and Prevention (CDC) to Glaxosmithkline, LLC as the prime contractor. The contract, valued at up to $1.25 billion, is part of the Vaccines for Children (VFC) 2015 program and provides for the delivery of various vaccines and pharmaceutical products to support federal immunization and disease prevention initiatives. Key products and services included under this multiple award IDV contract include seasonal influenza...
This federal Indefinite Delivery Contract (IDC) was awarded by the Centers for Disease Control and Prevention (CDC) to Glaxosmithkline, LLC, a foreign-owned, for-profit pharmaceutical company, for the procurement of adult vaccines. The IDC has a total ceiling value of $105,362,800 and a period of performance through June 30, 2026. The contract is a multiple award vehicle that does not have any set-aside designations. It supports critical national immunization efforts by allowing the CDC and...
This indefinite delivery contract (IDC) was awarded by the Centers for Disease Control and Prevention (CDC) to Glaxosmithkline, LLC, a pharmaceutical company, to provide adult influenza vaccines for the 2024-2025 season. The $13,916,000 multiple award IDC has a period of performance through February 28, 2025. The contract does not have any set-aside designations. Glaxosmithkline will likely provide the vaccines from its facilities in North Carolina to support the CDC's immunization programs...
This indefinite delivery contract (IDC) was awarded by the Centers for Disease Control and Prevention (CDC) to Glaxosmithkline, LLC, a foreign-owned, for-profit pharmaceutical company, to supply a variety of adult vaccines over a one-year period from July 1, 2023 through June 30, 2024. The total contract ceiling value is $232,487,206.61. The contract covers the procurement of an estimated 1.5 to 3 million doses of 12 different adult vaccines, including hepatitis A, hepatitis B, hepatitis A &...
The federal contract IDV award to Glaxosmithkline, LLC is for the supply of pediatric influenza vaccines to the Centers for Disease Control and Prevention (CDC) for distribution to immunization programs under the Section 317(j) Public Health Service Act and Vaccines for Children program. The single-award contract has a ceiling value of $161,025,000 and a period of performance from December 31, 2020 to February 28, 2022. The contract was issued in response to a CDC solicitation for a minimum...